Physician profile
Amber Buffinger
NPI 1740906411
$1,662.54
in general payments reported to CMS, 2019-2025
14 companies · $110 in 2025
The $110 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $17.67 · 2023: $1,278 · 2024: $257 · 2025: $110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,645.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,644.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $514.09 | 2023-2024 | |
| Lundbeck LLC | $156.36 | 2023-2024 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $152.00 | 2023 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $146.69 | 2023-2024 | Uzedy, Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $110.00 | 2025 | Cobenfy |
| Janssen Pharmaceuticals, INC | $107.40 | 2022-2023 | Invega Sustenna, Invega Trinza, Spravato |
| Alkermes, INC. | $98.93 | 2023-2024 | Aristada, Vivitrol, Lybalvi |
| Corium, LLC | $91.79 | 2023 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $70.35 | 2023-2024 | Rexulti, Abilify Maintena |
| Validus Pharmaceuticals LLC | $69.98 | 2023 | Equetro |
| Axsome Therapeutics, INC. | $57.22 | 2023 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.77 | 2023-2024 | Trulance, Xifaxan |
| Indivior INC. | $25.35 | 2023 | Sublocade |
| Takeda Pharmaceuticals U.S.A., INC. | $18.61 | 2023 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Buffinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.